Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Site License AIIRBS: Benefits Beyond Blood Pressure: Seeking Indications Throughout The Cardiovascular Continuum Datamonitor, Jan 2001   Description     Table of Contents        Enquire before Buying    Send to a Friend   An almost constant stream of trial results for Aiirbs in additional indicationscan be expected over the period to 2006/7. If these trials are positive, salesof the Aiirbs will increase dramatically.Being better tolerated than older anti-hypertensives and potentially effectivethroughout the cardiovascular continuum, the Aiirbs look set to dominate theanti-hypertensives market. Customers who bought this item also bought Strastegic Perspectives 2001: Diabetic Hypertension - Towards Aggressive, Individual and Holistic Treatment Strategies Market Dynamics 2001: Anti-hypertensives - Aiirbs battle for supremacy Treatment Algorithms: Hypertension 3rd Edition - Opportunities In Resistant and Hypertensive Sub-Populations Essential Hypertension and Its Causes: Neural and Non-Neural Mechanisms The Cardiovascular Outlook to 2007 Anti-hypertensives: Landmark clinical trial update - Commercial assessment of Charm, Comet, Ephesus and Europa Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices Cardiovascular Drug Delivery - Technologies, Markets and Companies ACE Inhibitor Intolerance: A major driver of growth for the Aiirbs Preventing Cardiovascular Events: Will HDL Therapeutics Change the Treatment Paradigm? Diabetes Diagnostics - Global Strategic Business Report Stakeholder Opinions: Diabetic Renal Disease

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster